Sterile inflammation characterized by unresolved chronic inflammation is well established to promote the progression of multiple autoimmune diseases, metabolic disorders, neurodegenerative diseases, and cardiovascular diseases, collectively termed as sterile inflammatory diseases. In recent years, substantial evidence has revealed that the inflammatory response is closely related to cardiovascular diseases. Cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway which is activated by cytoplasmic DNA promotes the activation of interferon regulatory factor 3 (IRF3) or nuclear factor-κB (NF-κB), thus leading to upregulation of the levels of inflammatory factors and interferons (IFNs). Therefore, studying the role of inflammation caused by cGAS-STING pathway in cardiovascular diseases could provide a new therapeutic target for cardiovascular diseases. This review focuses on that cGAS-STING-mediated inflammatory response in the progression of cardiovascular diseases and the prospects of cGAS or STING inhibitors for treatment of cardiovascular diseases.
27 April 2025 in Clinical and Translational Medicine
Background: Septic cardiomyopathy is a frequent complication in patients with sepsis and is associated with a high mortality rate. Given its clinical significance, understanding the precise underlying mechanism is of great value.Methods and results: Our results unveiled that Z‐DNA binding protein 1 (ZBP1) is upregulated in myocardial tissues of lipopolysaccharide (LPS)‐treated mice. Single‐cell mRNA sequencing (scRNA‐seq) and single‐nucleus mRNA sequencing (snRNA‐seq) indicated that Zbp1 mRNA in endothelial cells, fibroblasts and macrophages appeared to be elevated by LPS, which is partially consistent with the results of immunofluorescence. Through echocardiography, we identified that global deletion of ZBP1 improves cardiac dysfunction and the survival rate of LPS‐treated mice. Mechanistically, snRNA‐seq showed that ZBP1 is mainly expressed in macrophages and deletion of ZBP1 promotes the macrophage polarisation towards M2‐subtype, which reduces inflammatory cell infiltration. Notably, myeloid‐specific deficiency of ZBP1 also promotes M2 macrophage polarisation and improves cardiac dysfunction, validating the role of macrophage‐derived ZBP1 in septic myocardial dysfunction. Finally, we revealed that LPS increases the transcription and expression of ZBP1 through signal transducer and activator of transcription 1 (STAT1). Fludarabine, the inhibitor of STAT1, could also promote M2 macrophage polarisation and improve cardiac dysfunction of LPS‐treated mice.Conclusions: Our study provides evidence of a novel STAT1‐ZBP1 axis in macrophage promoting septic cardiomyopathy, and underscores the potential of macrophage‐derived ZBP1 as a therapeutic target for septic cardiomyopathy.Key points: Macrophage‐derived ZBP1 exacerbates LPS‐induced myocardial dysfunction and inflammatory cell infiltration. Deletion of ZBP1 promotes macrophage polarisation from M1 to M2. STAT1‐ZBP1 axis promotes septic cardiomyopathy. ZBP1 has emerged as a potential therapeutic target for inflammation and septic cardiomyopathy.
The combination of yellow‐emissive CsCu2I3 and blue‐emissive Cs3Cu2I5 for environmentally friendly white LEDs is demonstrated by Zhifeng Shi, Lijun Zhang, Chongxin Shan, and co‐workers in article number 2001367. Both copper halides are highly stable against heat, ultraviolet light, and oxygen/moisture degradation, as is demonstrated, and they use this strategy to overcome photon self‐absorption, color instability, and lead‐toxicity issues, which are among the challenges faced for perovskite white LEDs.
Ischemic heart disease (IHD) is the leading cause of death worldwide, accounting for over eight million deaths each year. IHD encompasses a spectrum of conditions, including atherosclerosis (AS), myocardial infarction (MI), and ischemia/reperfusion (I/R) injury. Programmed cell death (PCD) of endothelial cells (ECs) plays a critical role in IHD pathogenesis, causing microvascular dysfunction, barrier disruption and exacerbation of cardiac injury. PCD involves different signaling pathways, but they are interconnected. Therefore, it is crucial to understand the mechanisms underlying the various forms of PCD in ECs to develop therapeutic strategies for IHD. This review focuses on the molecular mechanisms of PCD of ECs in IHD and provides comprehensive summary of potential cell and gene therapy therapeutic strategies for the treatment of IHD.
Supplemental informantion included partial data which verified that ET is a direact cause of the side efforts of DOX and data which verified that mTOR signaling pathway play a role in DOX-induced systemic inflammation.